Gazette
masthead
   About The Gazette Search Back Issues Contact Us    
The newspaper of The Johns Hopkins University September 25, 2006 | Vol. 36 No. 4
 
MRIs Can Be Safe With Modern Defibrillators and Pacemakers

Risk is vastly reduced by using low-energy 'fix' for machine, and other steps

By David March
Johns Hopkins Medicine

Researchers at Johns Hopkins have painstakingly figured out how to safely perform magnetic resonance imaging scans on men and women who have any one of 24 modern types of implanted defibrillators and pacemakers.

Henry Halperin and his team have developed a combination of methods that reduces the risk of life-threatening meltdowns and other complications posed by MRI's ability to charge and manipulate the electrical properties of cells to produce real-time images from inside the body.

"We have turned a once exceptional procedure into one that is now a routine at Hopkins," Halperin said.

Among other things, the Johns Hopkins group reprograms the devices, fixing them to a specific sequence. This makes the implanted devices "blind" to their external environment, reducing the potential for their electronics to confuse the radiofrequency generated by the MRI with an irregular heartbeat and preventing misfires. The team also turns off the defibrillators' shocking function for the brief duration of the MRI scan, about 30 to 60 minutes.

Also changed is the amount of electrical energy used at peak scanning in MRI. The Johns Hopkins team reduced the strength of the electromagnetic field by half, from as much as 4 watts per kilogram to 2 watts per kilogram per patient.

"This lower-energy scan still provided images of sufficient quality to make an accurate diagnosis in more than 90 percent of cases tested," Halperin said in an article published in the Sept. 18 issue of the journal Circulation, reporting on 55 of more than 100 patients scanned at Johns Hopkins so far.

The report comes just two years after the same journal published the team's initial, positive findings in animals, stirring fierce debate at several international conferences as to whether or not MRI could truly be made safe.

The Johns Hopkins team says that since 2004 its expanded use of MRI has made more than a dozen potentially life-saving diagnoses, despite the fact that the tiny battery-driven heart devices, which help the body's main pump maintain a beat, have long been considered unsafe and off-limits for testing.

"The risk to patients of burning heart tissue or misfiring is still there," Halperin cautioned. "But our results show that with appropriate precautions, MRI is a safe and effective diagnostic tool to use for those with modern implanted heart devices." An electro-physiologist and professor of medicine, radiology and biomedical engineering at the School of Medicine and its Heart Institute, Halperin has long led efforts to expand access to MRI.

Except for research purposes, the U.S. Food and Drug Administration has not authorized any implanted cardiac device for MRI testing. But Halperin says that opening up this diagnostic option is important for the estimated 2 million Americans, many of them elderly, who have these implanted devices but who are also denied the benefits of the quick and accurate images that MRI provides.

Lead author Saman Nazarian, a cardiac electrophysiology, clinical and research fellow, said, "Once these precautions are better understood and further refined, we hope policy-makers will see fit to review current restrictions on scanning anyone with a device. These images are critical to early diagnosis of certain cancers of the brain, head and neck, and to guide invasive procedures."

Of those scanned in the study, 31 had a pacemaker and 24, an implantable defibrillator. Only modern devices — pacemakers made after 1996 and defibrillators manufactured after 2000 — were tested, Nazarian said, because the latest models were deemed to be safer than older versions. Newer models are made of titanium, a nonmagnetic metal; are smaller and more lightweight; and have better protection from the radiofrequency energy of the MRI scanner, he said.

Using a single scanner, a 1.5 Tesla by General Electric, the Johns Hopkins group was able to help plan artery-opening procedures for more than a half-dozen in the test group; improve measurements of tumor growth in nine others; and detect two strokes, a benign brain mass and a blood clot in the spine that had been missed by alternative imaging from CT scanning.

Nazarian cautions that only physicians specially trained in MRI safety, or with access to specialists familiar with the specific precautions taken in his study, should undertake this approach. "It is also important at this time to restrict MRI use to those with implanted devices specifically tested, and scanners of the same type and magnetic strength as that used in our study," he added.

All study participants were closely monitored during the scans with electrocardiography and pulse oximetry, and staff members were on hand to resuscitate patients in the event of an emergency.

All subjects were over age 19 and were followed from three months to six months to look for any post-test heart damage or changes in the devices' programming.

Patients were disqualified from testing if they had any leads placed on the surface of the heart or that were capped with metal and therefore not connected to the battery and at greater risk of overheating. When the leads — the electrical components connecting the device to the heart muscle — are attached to the battery or embedded in the blood vessels, they are less likely to be overheated by the MRI field.

An analysis of records showed that scans provided definitive answers to physicians' diagnostic questions 100 percent of the time for conditions affecting areas outside the chest and 93 percent of the time for conditions that affected the heart and the upper body; in the latter category, the remaining 7 percent of the scans were too distorted by imaging artifacts from the implanted devices to make a clear diagnosis.

Device monitoring showed that lead sensing did not fluctuate or change during the scan. Battery measurements showed that scans did not deplete or strengthen the battery's charge. Indeed, pacemakers and defibrillators performed successfully after the scans without any premature firing or false alarms.

Pacemakers and defibrillators are implantable devices used to treat people with an abnormal heartbeat, a condition known as arrhythmia. More than 2.2 million Americans are living with arrhythmia. It can occur in a healthy heart and be of minimal consequence or it can lead to more serious heart disease, stroke or sudden cardiac death.

Funding for this study was provided by the National Institutes of Health and the Donald W. Reynolds Foundation. Halperin is a paid consultant to defibrillator manufacturer Medtronic, and co-investigators Ronald Berger and Albert Lardo are paid consultants to Guidant Corp., another device manufacturer. Co-author David Bluemke has received honoraria from General Electric Health Care for presentations. None of these companies provided funding for the study, and the terms of the physicians' arrangements are managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.

Other investigators in this research, conducted solely at Johns Hopkins, were Ariel Roguin, Menekhem Zviman, Timm Dickfeld, Robert G. Weiss and Hugh Calkins.

GO TO SEPTEMBER 25, 2006 TABLE OF CONTENTS.
GO TO THE GAZETTE FRONT PAGE.


The Gazette | The Johns Hopkins University | Suite 540 | 901 S. Bond St. | Baltimore, MD 21231 | 443-287-9900 | gazette@jhu.edu